Emergence of Low-level Delamanid and Bedaquiline Resistance During Extremely Drug-resistant Tuberculosis Treatment

Clin Infect Dis. 2019 Sep 13;69(7):1229-1231. doi: 10.1093/cid/ciz074.

Abstract

Two new drugs, delamanid and bedaquiline, have recently been approved for treatment of multidrug-resistant and extensively drug-resistant (XDR) tuberculosis. Here, we report a case of clofazimine, bedaquiline, and low-level delamanid resistances acquired during treatment of a patient with XDR tuberculosis.

Keywords: XDR-tuberculosis; bedaquiline resistance; delamanid resistance.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antitubercular Agents / pharmacology
  • Antitubercular Agents / therapeutic use*
  • Diarylquinolines / pharmacokinetics
  • Diarylquinolines / therapeutic use*
  • Drug Resistance, Bacterial*
  • Drug Therapy, Combination
  • Extensively Drug-Resistant Tuberculosis / diagnosis
  • Extensively Drug-Resistant Tuberculosis / drug therapy*
  • Extensively Drug-Resistant Tuberculosis / microbiology*
  • Humans
  • Male
  • Microbial Sensitivity Tests
  • Middle Aged
  • Mycobacterium tuberculosis / drug effects*
  • Nitroimidazoles / pharmacology
  • Nitroimidazoles / therapeutic use*
  • Oxazoles / pharmacology
  • Oxazoles / therapeutic use*
  • Treatment Outcome

Substances

  • Antitubercular Agents
  • Diarylquinolines
  • Nitroimidazoles
  • OPC-67683
  • Oxazoles
  • bedaquiline